Elucida Oncology adds former BELLUS financial leader to management team as CFO

Ramzi Benamar joins Monmouth Junction life sciences firm's executive staff

Scientific pocket calculator and test tube at workplace

Monmouth Junction-based Elucida Oncology on Thursday announced that Ramzi Benamar, a seasoned financial leader with a proven track record in the life sciences industry, has been appointed as chief financial officer, effective Sept. 1.

“We are very excited to welcome Ramzi to our management team at this pivotal phase of Elucida’s growth and development. With the promising early clinical data emerging from our proprietary (C’Dot drug conjugate) platform technology, Ramzi’s extensive experience in corporate finance, strategy and operations, as well as his track record of financing clinical-stage biotech companies, will be critical as we continue down our path to exceed current standards in targeted cancer therapy,” Geno Germano, CEO and president of Elucida Oncology, said.

Prior to Elucida, Benamar was the chief financial officer of BELLUS Health, a clinical-stage biotech company that was recently acquired by GSK PLC for $2 billion. He was instrumental in strengthening the company’s balance sheet by raising $400 million overall and contributed to the development and execution of the corporate strategy.

Prior to BELLUS Health, Benamar was chief financial officer of DBV Technologies, where he led the global finance team and raised over $160 million. Previously, he was vice president and head of financial planning and analysis for Spark Therapeutics until its acquisition by Roche Holdings. Earlier in his career, Benamar held numerous positions of increasing responsibilities in finance and operations at various pharma companies including Shire, Johnson & Johnson and Merck.

Benamar holds a bachelor’s and MBA from Temple University, and a master’s degree from Saint Joseph’s University (University of the Sciences in Philadelphia).

“I am thrilled to be joining Elucida and excited about the potential to deliver transformative therapies to cancer patients. I look forward to becoming part of the Elucida team and contributing to further advance the C’Dot drug conjugate platform,” Benamar said.